Long-Term Safety and Effectiveness of Adalimumab for Moderate to Severe Psoriasis: Results from 7-Year Interim Analysis of the ESPRIT Registry.

ABSTRACT:

Introduction

ESPRIT (NCT00799877) is an ongoing 10-year international prospective observational registry evaluating the long-term safety and effectiveness of originator adalimumab in routine clinical practice for adult patients with chronic plaque psoriasis. Herein, we report the long-term safety, effectiveness, and patient-reported outcomes (PROs) following adalimumab treatment over the first 7 years of the ESPRIT registry.

Methods

All treatment-emergent (All-TE) adverse events (AE) since the initial (first ever) dose of adalimumab were assessed. Physician Global Assessment (PGA) and PROs (PROs for US patients only) were evaluated during registry participation.

Results

As of 30 November 2015, 6051 patients in the ESPRIT registry were analyzed, representing 23,660.1 p

SUBMITTER: Menter A 

PROVIDER: S-EPMC5574748 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature